10+
installs · ≈16
—
0 ratings
2025-03-13
first release
2026-02-03
last update
Description
Study for Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC
This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
What's new
Bug fixes and performance improvements
Details
| Version | 5.4.1100.1-prod |
|---|---|
| Minimum Android version | 8.0 |
| Reviews | 0 |
| Available in | American Samoa, Austria, Australia, Åland Islands, Belgium, Bulgaria, St. Barthélemy, Brazil, Canada, Switzerland, Chile, China and 53 more |
| Developer contacts | on the Business plan |
| Collected | 2026-11-15 |
This data in the API
The full record in JSON costs 1 token.
curl -H "X-API-Key: YOUR_KEY" \ "https://apkapi.com/api/v1/app?id=com.medable.lilly.jzqh"
